METHODS	We genotyped 1,778 acute coronary syndrome patients within the PROVE IT-TIMI 22 ( Pravastatin or Atorvastatin Evaluation and Infection Therapy : Thrombolysis in Myocardial Infarction 22 ) trial and investigated different intensities of statin therapy in carriers of 719Arg and in noncarriers using Cox proportional hazards models that adjusted for traditional risk factors .\